STAA Staar Surgical Co.

$STAA Love it when the new mgmt additions still have glasses in their profile pic. Obv it's because they're too old, but just puts a bad taste in your mouth to see them not practice what they preach 😂

$STAA -Disaster- coming up on the one year anniversary of turning down a 30.75 bid - nice work Broadwood,Yunqi

$STAA -really starting to sour on Broadwood Bradsher. Runs 1.6 billion- holds 6 positions - 3 of them on their lows(STAA, IMDX, LCTX) . Staying long STAA - but it's getting tiresome

$STAA Neal continues to communicate to us in code. Today's BD appointment from JNJ was to foreshadow the acquieree. The $50M repurchase authorization foreshadows the buyout price of $50, and David Bailey rejoining implies it will be sooner than later

Stifel upgraded STAAR Surgical from Hold to Buy and raised its price target to $31 from $28, citing an attractive entry point and potential for sustained, profitable double-digit revenue growth. Analyst Thomas Stephan expects a favorable product mix shift toward the higher-priced EVO+ implantable collamer lens in China, combined with easier year-over-year comparisons outside China, to drive a meaningful sales inflection in the second half of 2026. Stifel’s scenario analysis projects an 11% compound annual growth rate in sales from 2026 to 2028, above the roughly 8% consensus estimate. The upgrade also follows STAAR’s authorization of a $50 million share-repurchase program, funded by free cash flow and available cash, which management said reflects confidence in the company’s financial strength and view that the shares are undervalued. The company’s exposure to a recovering refractive market in China also supports the thesis. $STAA